Novel microfluidic electrochemical biosensor for rapid diagnosis of biomarkers

免疫传感器在不同类型的生物传感器中是非常著名的，用于快速诊断体液中的生物标记物。免疫传感器的标签格式允许在广泛的检测方案中灵活地实施生物传感。然而，这些系统在对复杂生物样品中的几分钟分子进行非常高灵敏的检测方面受到限制。在将报告分子引入基于标记的过程中，还需要在时间、成本和额外步骤方面进行权衡。此外，在护理设备中使用光学检测系统在单个多路生物传感器中同时检测多个生物标志物有另一个限制，因为它们需要外部光源、光学换能器和其他光学部件，如透镜和反射器，这使得检测系统变得笨重和复杂。在各种类型的无标记检测技术中，电化学传感是集成最简单、灵敏度最高、与多路复用和集成到微流体中的兼容性最强的技术，这使得它成为理想的护理点诊断技术。在本工作中，我们将开发一种集成的、自主的微流体生物传感器，用于快速检测脑损伤生物标志物。将开发一种新的粘合技术，将电极非侵入性地粘贴到微流体层上，以实现电极的高效性能和生物标志物的护理点检测。如果成功，本文提出的微流控纳米生物传感器将在不到一小时的时间内用于患者血液样本中三种不同的脑损伤生物标志物的快速诊断。申请人在微流体和生物传感器方面的专业知识确保了该项目的成功。SensorealInc.将受益于无标签生物传感器，以扩大其技术的应用，使用护理点诊断技术快速和自动检测人类生物样本中的多个生物标记物。较低的成本和可预见点的护理传感器将使快速和大规模的疾病筛查成为可能，并有助于监测疗法的疗效，因此有利于加拿大的卫生系统。

Immunosensors are very known among different types of biosensors for rapid diagnosis of biomarkers in bodilyfluids. The label-format of immunosensors allows for flexible implementation of biosensing in a wide range ofdetection schemes. However, these systems are limited in very high sensitive detection of minutes of moleculesin complex biological samples. There is also a trade-off in the time, cost and additional steps associated withincorporating reporter molecules into the label-based process. Moreover, the use of optical detection systems inpoint-of-care devices has one more constraint in detection of multiple biomarkers simultaneously in a singlemultiplexed biosensor as they require an external light source, optical transducer and other optical componentslike lenses and reflectors, which makes the detection system bulky and complex. Among various types oflabel-free detection techniques, the electrochemical sensing is the simplest to integrate, highly sensitive andmore compatible with multiplexing and integration into microfluidics, which makes it ideal for point-of-carediagnosis.In this work, we will develop an integrated and autonomous microfluidic-based biosensor for rapid detection ofbrain injury biomarkers. A new bonding technology will be developed to adhere electrodes to microfluidiclayers noninvasively to enable efficient performance of electrodes and point-of-care detection of biomarkers. Ifsuccessful, the microfluidic nano-biosensor proposed in this work will be used for rapid diagnosis of threedifferent biomarkers of brain injury in blood samples of patients in less than an hour. The expertise of theapplicant in microfluidics and biosensors ensures the success of this project.Sensoreal Inc. will benefit from label-free biosensors to extend the application of their technology for rapid andautomated detection of multiple biomarkers in human biological samples using a point-of-care diagnostictechnology. The lower cost and predictive point of care sensors will enable the rapid and large scale diseasescreening and facilitate monitoring the efficacy of therapeutics, therefore benefit the health system in Canada.